AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)
| CAPS Rating |
|
|---|
AVEO
VS S&P 500 (SPY)
AVEO News and Commentary
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3 – SeekingAlpha
- AVEO's AV-203 in Phase I - Analyst Blog – NASDAQ
- An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABP – 247wallst
- Ariad Pharmaceuticals, ArQule, Exelixis, Aveo, Other Cancer Drug Stocks Fall – Minyanville
- Drug Fails: At Least It's Approved Already – The Motley Fool
- Bearish MACD for AVEO Pharmaceuticals, Inc. - Tale of the Tape – NASDAQ
- Cancer Cures: ASCO Stocks to Give Your Portfolio a Boost – The Motley Fool
- Hedge Funds: Seth Klarman's Baupost Top Holdings – The Motley Fool
- Kidney Cancer? There's a Drug for That – The Motley Fool
How do you think AVEO will perform against the market?
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPSAll Players
43
Outperform
27
Underperform
All-Star Players
14
Outperform
10
Underperform
Wall Street
2
Outperform
0
Underperform
RSS Headlines
Fool UK
